Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4205 in relapsed/refractory peripheral T cell lymphoma
NCT06511895Phase 2Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- May 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of golixitinib in peripheral T-cell lymphoma (PTCL), sponsored by Dizal Pharmaceutical Co., Ltd.. Started May 2022; status: completed.
02
Drugs
golixitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06511895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06511895.